Table 1.
Coagulation factor activities of the single lots measured for the five different PCCs.
Figure 1.
Prothrombin times (PT in sec, panel A), activated partial thromboplastin times (aPTT in sec, panel B), fibrinogen levels (in g/L, panel C), as well as the plasma thrombin generation characteristics lag time (in min, panel D), peak height (in nM thrombin, panel E), and velocity index (in nM/min, panel F) for plasmas derived from whole blood diluted with Ringers Lactate (RL) to obtain undiluted and 80, 60, 40, and 20% whole blood.
Solid lines indicate control blood without addition of fibrinogen and dashed lines indicate diluted whole blood to which fibrinogen was added in order to obtain a final concentration of approximately 2.5 g/L. Data are presented as median with IQR, *indicates p<0.05.
Figure 2.
ExTem (upper panel) and InTem (lower panel) derived thromboelastometry (ROTEM) parameters from whole blood diluted with Ringers Lactate (RL) to obtain undiluted and 80, 60, 40, and 20% whole blood.
Solid lines indicate control blood without addition of fibrinogen and dashed lines indicate diluted whole blood to which fibrinogen was added in order to obtain a final concentration of approximately 2.5 g/L. Panel A and D: Clotting times (CT in sec), panel B and E: maximum clot firmness (MCF in mm), and panel C and F: alfa-angle (in degrees). Data are presented as median with IQR, *indicates p<0.05.
Figure 3.
Prothrombin times (PT in sec, panel A and B) and activated partial thromboplastin times (aPTT in sec, panel C and D) for plasmas derived from whole blood diluted with Ringers Lactate (RL) to obtain undiluted and 80, 60, 40, and 20% whole blood.
Before preparation of plasma, PCCs were added to undiluted (100%) and diluted (80, 60, 40, and 20%) whole blood (panels A and C). To correct for fibrinogen dilution, whole blood was supplemented with fibrinogen in order to obtain a final concentration of approximately 2.5 g/L at each dilution (panels B and D). Control (green), CoFact 500 I.E. (red), Beriplex P/N 250 (gold), Prothromplex NF 600 (aqua), Octaplex 500 (blue), and PPSB-human SD/Nano 600 (purple). Data are presented as mean with SEM.
Figure 4.
Plasma thrombin generation, triggered with 5 pM tissue factor, parameters lag time (in min, panel A and D), peak height (in nM thrombin, panel B and E), and velocity index (in nM/min, panel C and F) for plasmas derived from whole blood (100%) diluted with Ringers Lactate (RL) to obtain 80, 60, 40, and 20% whole blood.
Before preparation of plasma, PCCs were added to undiluted (100%) and diluted (80, 60, 40, and 20%) whole blood (panels A, B, and C). To correct for fibrinogen dilution, whole blood was supplemented with fibrinogen in order to obtain a final concentration of approximately 2.5 g/L at each dilution (panels D, E, and F). Control (green), CoFact 500 I.E. (red), Beriplex P/N 250 (gold), Prothromplex NF 600 (aqua), Octaplex 500 (blue), and PPSB-human SD/Nano 600 (purple). Data are presented as mean with SEM.
Figure 5.
Thromboelastometry (ROTEM), triggered with ExTem reagent, parameters coagulation time (CT in sec, panel A and D), maximum clot firmness (MCF in mm, panel B and E), and α-angle (in degrees, panel C and F) for samples derived from whole blood (100%) diluted with Ringers Lactate (RL) to obtain 70, and 40% whole blood.
PCCs were added to undiluted (100%) and diluted (70 and 40%) whole blood. To correct for fibrinogen dilution, whole blood was supplemented with fibrinogen in order to obtain a final concentration of approximately 2.5 g/L at each dilution (panels D, E, and F). Control (green), CoFact 500 I.E. (red), Beriplex P/N 250 (gold), Prothromplex NF 600 (aqua), Octaplex 500 (blue), and PPSB-human SD/Nano 600 (purple). Data are presented as median with IQR.
Figure 6.
Thromboelastometry (ROTEM), triggered with InTem reagent, parameters coagulation time (CT in sec, panel A and D), maximum clot firmness (MCF in mm, panel B and E), and α-angle (in degrees, panel C and F) for samples derived from whole blood (100%) diluted with Ringers Lactate (RL) to obtain 70, and 40% whole blood.
PCCs were added to undiluted (100%) and diluted (70 and 40%) whole blood. To correct for fibrinogen dilution, whole blood was supplemented with fibrinogen in order to obtain a final concentration of approximately 2.5 g/L at each dilution (panels D, E, and F). Control (green), CoFact 500 I.E. (red), Beriplex P/N 250 (gold), Prothromplex NF 600 (aqua), Octaplex 500 (blue), and PPSB-human SD/Nano 600 (purple). Data are presented as median with IQR.